Who can "send a little red flower" to cancer patients in 2021?

"Don't give up love and hope, every brave man who fights against the trend and fate deserves to be rewarded with a 'little red flower'.
" - "Send you a little red flower" 2021 New Year's movie "Send you a little red flower" contracted fans to laugh, but also earned their tears.
this is Director Han Yan's follow-up to Get Out of Here! Tumor Jun is followed by another movie focused on the cancer community, "Send You a Little Red Flower" presents the story of mutual assistance and self-rescue among cancer patients, as well as the story of actively fighting cancer tenaciously moved many people.
The revelation of cancer-themed films: Cancer is not far away in recent years, anti-cancer-themed movies or TV series are becoming more and more, these films and television works are also reminding us: cancer, not far away from us, with the rising prevalence of more and more patients are suffering from cancer.
the latest figures released by the International Agency for Research on Cancer (IARC), part of the World Health Organization, there will be about 19.3 million new cancer cases and about 10 million deaths worldwide by 2020.
And China's national cancer registration testing point reported data show that: China's annual new cancer cases of about 3.929 million cases, the incidence rate is close to the world average;
The annual number of cancer deaths in China is about 2.338 million, and the mortality rate is higher than the world average;
increasing cancer rates are put enormous pressure on care, and many patients are waiting for good treatment to help them get rid of the disease.
immunocellular therapy, to give patients a hope of "little red flower" we know that the general traditional way of cancer treatment is surgery, chemotherapy and so on.
The treatment of cancer has changed dramatically in recent years, with more and more advanced treatment options available to cancer patients today, in addition to traditional surgery, radiotherapy and chemotherapy, such as targeted medication, immunotherapy, and cell therapy.
with the progress of science and technology, more and more new technologies are driving the development of human anti-cancer history, but also for human "conquering" cancer more hope.
2017, cancer immunocellular therapy was first approved, and this is the car-T cell therapy that is often seen.
, three CAR-T cell therapies have been approved worldwide: Novaral Kymriah, Gilead Yescarta and Tecartus.
the development of immunocellular therapy, patients are being given the hope of "little red flowers."
is immunocellular therapy? Immunocellular therapy is the collection of human autoimmune cells, after in vitro culture or modified culture, so that its number increased thousands of times, and stimulate vitality, and then back into the body, killing cancer cells and mutant cells in the body.
activates and enhances the body's immunity, effectively controlling the metastasis and recurrence of cancer cells.
In recent years, with the development of science, clinically began to use engineered immune cells to treat malignant blood system diseases (leukemia, etc.), while these "designed" immune cells have also been applied to liver cancer, lung cancer and other solid tumors in clinical research, the efficacy is very significant, this method is considered to be a milestone in the fight against cancer in humans.
01 Using T-cells to treat leukemia scientists "designed" T-cells and installed a "plug-in" -CAR with a "radar" function that allows them to accurately identify and kill cancer cells, a car-T immunotherapy that has been hot in recent years.
In September 2019, 12 of the 14 children with acute lymphoblastic leukemia (12 of whom remained healthy) who were tested for CAR-T immunocytocytotherapy at Great Ormond Street Hospital in London were cured within three months.
02 The use of NK cells to treat non-Hodgkin's lymphoma and leukemia another immune cell - NK cells (natural killer cells) and T cell therapy constitute a double male sword of immunotherapy, is another cancer potential unit.
20 years ago, NK cell-mediated immunotherapy was considered a safe and effective treatment for patients with advanced leukemia.
recent years, the field of cancer treatment based on NK cells has grown exponentially and has become the main area of immunotherapy innovation.
recent years, scientists have designed NK cells similar to "CAR-T" cells, forming "CAR-NK" cells.
scientific research has found that this CAR-NK has significant advantages.
The results of a recent phase I/IIa trial at the MD Anderson Cancer Center showed that in combination antigen-donor cell therapy (CAR-NK) cell therapy, which targets CD19, showed clinical efficacy in most patients with recurring/refractic non-Hodgkin's lymphoma (NHL) and patients with chronic lymphocytic leukemia (CLL) and no significant toxic reactions were observed.
8 (73%) of the 11 patients who participated in the study responded to the treatment, and 7 of them achieved complete remission.
5 patients who responded continued to receive post-remission treatment, and no patients developed cytokine release syndrome or neurotoxicity.
response to CD19 CAR-NK cell therapy within 1 month of infusion and confirmed the persistence of these cells within 1 year of infusion.
03 The treatment of re-emerged tumor degenerate cells (DC cells) with degenerate deuterium cells is used to induce the production of degenerate deutergenal cells by using a single nuclear cell of the patient's own body, to make DC cells containing tumor antigens, and then inject these DC cells into the patient's body, play a long-term role in monitoring tumors and killing tumors, in order to eliminate tumors.
from early 2013 to March 2014, the team in Gothenburg, Sweden, used DC cell therapy to conduct clinical trials on 12 patients with metastatic renal cell carcinoma (NCT01525017).
June 2017, they published results showing that the treatment was very safe and did not have serious adverse events associated with the treatment.
as of December 2016, the average lifetime of 11 assessable patients was 42.5 months compared to available historical data.
by the end of May 2017, five patients who participated in the study were still alive, reaching a final mid-life of 48.0 months.
"I'm not afraid of disease, I can beat it!" "It's a slogan that cancer patients in "A Little Red Flower" encourage each other to cheer on.
The film also tells us that there is no point in retreating and escaping in the face of cancer, that only positive responses can increase the likely survival, and that advances in medical technology will help us overcome the disease.
as an emerging force, immunocell therapy is giving cancer patients hope of a cure, believing that in the future, immunocell therapy will help more patients to regeneration, giving them hope of "little red flowers."
references: s1) s1 s CD19 CAR NK-cell therapy achieves 73% response rate in patients with leukemia and lymphoma